Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer

Suppression of gonadal testosterone synthesis represents the standard first line therapy for treatment of metastatic prostate cancer. However, in the majority of patients who develop castration-resistant prostate cancer (CRPC), it is possible to detect persistent activation of the androgen receptor...

Full description

Bibliographic Details
Main Authors: Stein, Mark N, Patel, Neal, Bershadskiy, Alexander, Sokoloff, Alisa, Singer, Eric A
Format: Online
Language:English
Published: Medknow Publications & Media Pvt Ltd 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023364/

Similar Items

Similar Items